Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
706 BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
